ERAP2作为卵巢衰老及POI自发排卵恢复的潜在标志物
该前瞻性队列研究纳入60例早发性卵巢功能不全(POI)患者和60例对照,通过机器学习从公共转录组数据筛选出ERAP2,并验证其血清水平在POI患者中显著升高。随访4年发现,血清ERAP2可预测POI患者卵巢功能间歇性恢复和临床妊娠,将其加入现有指标可显著提高预测准确性。
要点
- POI患者血清ERAP2水平显著高于对照(5.78±2.29 vs 4.81±2.20 ng/mL,p=0.018)。
- ERAP2预测卵巢功能间歇性恢复的AUROC为0.763(95%CI 0.734-0.792)。
- ERAP2预测临床妊娠的AUROC为0.768(95%CI 0.749-0.787)。
核心结论
- 血清ERAP2可作为POI患者卵巢功能间歇性恢复和临床妊娠的生物标志物。
- 将ERAP2与其他临床指标结合可能有助于POI患者的个体化干预策略。
研究设计与样本
- 前瞻性队列研究,纳入60例POI患者和60例对照女性,2018至2019年招募自山东大学附属生殖医院。
- 利用机器学习算法从公共卵巢转录组数据筛选卵巢衰老特征,并比较两组血清ERAP2水平。
- 对POI患者进行4年前瞻性随访,基于血清ERAP2水平建立卵巢功能间歇性恢复和临床妊娠的预测模型。
主要发现
- 机器学习模型识别ERAP2为与卵巢衰老相关的新生物标志物。
- POI患者血清ERAP2水平显著高于对照(5.78±2.29 ng/mL vs. 4.81±2.20 ng/mL,p=0.018)。
- ERAP2预测卵巢功能间歇性恢复的AUROC为0.763(95%CI 0.734-0.792)。
- ERAP2预测临床妊娠的AUROC为0.768(95%CI 0.749-0.787)。
- 将ERAP2加入现有指标显著提高预测卵巢功能间歇性恢复的准确性(IDI=0.166,p=0.008)。
关键数值与推荐
- POI患者血清ERAP2水平为5.78±2.29 ng/mL,对照为4.81±2.20 ng/mL,组间比较p=0.018。
- ERAP2预测卵巢功能间歇性恢复的AUROC=0.763(95%CI 0.734-0.792)。
- ERAP2预测临床妊娠的AUROC=0.768(95%CI 0.749-0.787)。
- 加入ERAP2后预测卵巢功能间歇性恢复的IDI=0.166(p=0.008)。
- 加入ERAP2后预测临床妊娠的NRI=0.442(p=0.034)、IDI=0.208(p=0.018)。
临床怎么用
- 临床可考虑检测POI患者血清ERAP2水平,辅助预测卵巢功能间歇性恢复和临床妊娠。
- 将ERAP2与现有临床指标联合使用,可能提高对POI患者预后判断的准确性。
- 基于ERAP2的预测模型或有助于制定POI患者的个体化干预策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore novel biomarkers for clinical prognosis in patients with ovarian ageing, especially in premature ovarian insufficiency (POI). DESIGN: Prospective Cohort Study. SETTING: Reproductive Hospital Affiliated with Shandong University, China. POPULATION: Sixty POI patients and 60 control women recruited from 2018 to 2019. METHODS: Machine learning algorithms were used to screen features of ovarian ageing from public ovarian transcriptome data. The candidate serum biomarker, endoplasmic reticulum aminopeptidase-2 (ERAP2), was compared between 60 POI patients and 60 control women. A prospective follow-up of 4 years was conducted on POI patients, and prediction models were established for intermittent recovery of ovarian function and clinical pregnancy based on serum ERAP2 levels. MAIN OUTCOME MEASURES: Intermittent recovery of ovarian function and clinical pregnancy. RESULTS: Machine learning models identified ERAP2 as a novel biomarker associated with ovarian ageing. POI patients exhibited significantly elevated serum ERAP2 levels compared to controls (5.78 ± 2.29 ng/mL vs. 4.81 ± 2.20 ng/mL, p = 0.018). With a prospective follow-up of these POI patients, ERAP2 was found to be a new biomarker for predicting intermittent recovery of ovarian function (AUROC = 0.763, 95% CI 0.734-0.792) and clinical pregnancy (AUROC = 0.768, 95% CI 0.749-0.787). Integrating ERAP2 into existing indices significantly improved their prediction accuracy both in predicting intermittent recovery of ovarian function (IDI = 0.166, p = 0.008) and in clinical pregnancy (NRI = 0.442, p = 0.034; IDI = 0.208, p = 0.018). CONCLUSIONS: Serum ERAP2 can serve as a biomarker for intermittent recovery of ovarian function and clinical pregnancy in patients with POI. Combining ERAP2 with other clinical indicators may facilitate personalised intervention strategies for patients with POI in clinic.
引用
- Meng T, Jo Y, Wei S, et al. ERAP2 as a Potential Marker for Ovarian Ageing and Spontaneous Ovulation Recovery in Women With Premature Ovarian Insufficiency. BJOG. 2025. PMID: 41340593. doi:10.1111/1471-0528.70105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。